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Abstract
Objective—To compare the incidence rates of malignancy among psoriatic arthritis (PsA) and
rheumatoid arthritis (RA) patients in the Consortium of Rheumatology Researchers of North
America (CORRONA) registry.
Methods—We analyzed 2,970 PsA patients with 7133 patient years (PY) of follow-up, and
19,260 RA patients with 53864 PY of follow-up. Using a standardized adjudication process, we
identified 40 confirmed malignancies in PsA and 307 confirmed malignancies in RA. Incidence
rates (IRs) were calculated per 100 PY. Incidence rate ratios (IRRs) were estimated, adjusted for
age, gender, disease duration, body mass index, disease activity, year of enrollment, and
medication use.
Results—The overall malignancy incidence per 100 PY was similar between PsA and RA
patients, 0.56 (95% CI 0.40, 0.76) for PsA and 0.56 (95% CI 0.50, 0.63) for RA. Non-melanoma
skin cancer was the most common type of cancer in the overall cohort, with an IR of 0.21 (95%CI
0.12, 0.35) in PsA, and 0.20 (95%CI 0.17, 0.24) in RA, with a calculated IRR of 1.05 (95%CI
0.61, 1.80), p=0.85. Lymphoma rates were similar in PsA vs. RA, 0.04 (95% CI 0.01, 0.12) vs.
0.04 (95% CI 0.02, 0.06), IRR 1.00 (0.17, 3.11), p=0.67. The adjusted IRR of malignancy in PsA
vs. RA was 1.18 (0.82, 1.69), p=0.37).
Conclusion—The incidence rate across malignancy subtypes were similar in PsA and RA
cohorts from a United States registry.
Psoriatic arthritis (PsA) is a multisystem inflammatory disease characterized by
inflammation of both skin and joints. Therefore, PsA shares some clinical features of both
rheumatoid arthritis (RA) and skin psoriasis (PsO), where malignancy risk has been more
extensively studied. Several large cohort studies have found an increased overall risk of
malignancy (1, 2) as well as lymphoma and hematologic cancers (3, 4) in RA compared with
the general population. Similarly, a higher incidence of malignancy has been demonstrated
in patients with PsO (5–7), including non-melanoma skin cancers (7, 8) and lymphoma (9).
It is unclear whether malignancy risk in PsA can be extrapolated from previous studies of
patients with RA and PsO. For example, patients with RA have been found to have higher
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levels of disease activity such as tender and swollen joint counts and ESR, and more
radiographic damage than patients with PsA (10). This may lead to a possible decreased risk
of malignancy in PsA patients as compared to their RA counterparts given that chronic
inflammation is a risk factor for certain malignancies in patients with inflammatory arthritis
(11). In contrast, the additive impact of inflammation from both skin and joint disease may
put PsA patients at increased risk of malignancy as compared to those with RA or PsO who
have solely skin disease or joint disease alone. To date there has been only one large
prospective study of 665 patients from Canada that examined incidence of malignancy in
patients with PsA and showed that malignancy rates were not higher in PsA compared with
the general population (12). Based on our literature review, there are no studies comparing
the incidence of malignancy and factors associated with malignancy in PsA and RA.
Therefore, we compared the incidence of malignancy between PsA and RA patients enrolled
in the Consortium of Rheumatology Researchers of North America (CORRONA) registry, a
large prospective United States (U.S.) cohort. In addition, we evaluated demographic and
disease-related variables associated with malignancy in both PsA and RA. We hypothesized
that malignancy rates will be similar between PsA and RA patients in CORRONA.
Methods
CORRONA registry description
CORRONA is a multi-centered, longitudinal registry which includes 85 academic and
private clinical sites across the U.S., with 4216 PsA and 26133 RA patients enrolled from
August 2003 to October 2010. The details of CORRONA registry have been previously
published (13). Briefly, clinical information of enrolled subjects including disease duration,
comorbidities, medications, measures of disease activity, and adverse events is collected
using comprehensive questionnaires completed by both patients and participating
rheumatologists. Prior to 2013, the CORRONA PsA registry did not collect information on
axial disease or skin disease in PsA and did not collect identifying data that would enable
linking the information from the CORRONA registry to the National Death Index Database
or other national databases. Questionnaires were completed at patient enrollment and
follow-up encounters requested at three to six month intervals. The CORRONA registry is
approved by the institutional review boards of participating academic sites and a central
institutional review board for community-based private sites. All patients sign informed
consent before participation.
Study Population
We included all PsA and RA patients followed in the CORRONA registries between August
2003 and October 2010 who had at least 2 study visits during this time period. In order to
capture the incidence of new malignancy, we excluded patients with a prior history of
malignancy and patients with only one CORRONA visit, similar to other studies (14, 15).
History of malignancy was documented in the physician form and based on either patient
report or medical records. Additional cases of prior malignancy history were found during
adjudication process (see below).
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Malignancy adjudication
We used a previously validated structured adjudication process described elsewhere (16).
Briefly, we examined cases of physician-reported malignancies that are initially reported at
follow-up study visits, and subsequently confirmed using an adverse event form completed
by the rheumatologist at the reporting site. Supporting medical records such as biopsy
reports, oncology specialist office notes, etc. are collected by the patient’s rheumatologist
and sent to CORRONA for centralized adjudication. Adverse event forms and source
documents were independently reviewed by two investigators, with a third reviewer serving
as a “tiebreaker.” Cases of malignancy were classified as “definite,” “probable,” “possible,”
and “not a malignancy.” Only cases that had both the date of diagnosis and histology
information were deemed “definite” or “probable” and considered confirmed incident
malignancies. For patients with more than one malignancy reported during the follow-up
period, only the first event was used in the analysis.
Statistical Analysis
For patients with malignancy, variables were compared at the CORRONA follow-up visit
where the malignancy was reported. For patients without malignancy, variables were
compared at the last recorded follow-up visit. We used the student’s t-test (or its non-
parametric alternative, Wilcoxon rank sum test) to evaluate the differences between
distributions of continuous variables, and chi-square (or Fisher’s exact test when
appropriate) to evaluate the association between categorical variables. Differences were
considered statistically significant if p<0.05 (two-tailed). Continuous variables were
reported as mean ± standard deviation (SD). Categorical variables were reported as
percentages and frequencies.
First, we calculated the incidence rates of total confirmed malignancies and specific
malignancies types with 95% confidence intervals (CIs) for both PsA and RA groups. Then,
we used multivariate Poisson and Cox regression models to derive the incidence rate ratios
(IRRs) and hazard ratios (HRs) of overall malignancy rates among PsA and RA patients in
CORRONA and to test the significance of an indicator variable for PsA vs. RA. Our final
models were adjusted for age (in 5-year increments), sex, race, year of enrollment into
CORRONA, disease duration, disease activity measures, smoking, alcohol use, BMI, and
family history of malignancy.
Following 2010 EULAR recommendations for reporting results from biologics registries in
rheumatology (17), we conducted several sensitivity analyses and used various definitions of
disease activity and medication exposures to study an association between malignancy
incidence and disease state (PsA vs. RA). Disease activity measures, CDAI and mHAQ,
were examined as continuous variables and categorical variables (18), as well as cumulative
scores, defined as a cumulative average over each time interval during follow-up). Smoking
was analyzed as past smoker, and current smoker compared to “never smoked.” Age was
analyzed as a continuous variable and as a time scale variable for survival analysis and for
Poisson regression models. Since we were interested in comparing the incidence of
malignancy between PsA and RA, and because we obtained similar results using survival
analysis and Poisson regression models, we only presented Poisson regression models in the
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manuscript. Our final regression models were tested for overdispersion (p>0.99)
demonstrating an appropriate model fit (19).
For our main analyses, we also included use of biologics and DMARDs which were
analyzed as “ever exposed” given the likely longer term effects of DMARDs on malignancy
risk. In an effort to account for the duration of the medication exposure, we also conducted
additional sensitivity analyses using the following 5 mutually exclusive medication
categories: current methotrexate without current or prior biologic use; current biologic
without current or prior methotrexate use; current biologic with current or prior
methotrexate use; non-methotrexate DMARD with prior methotrexate use only, and no
current or prior biologic use; and non-methotrexate DMARD without current or prior
methotrexate or biologic. In this analysis some patients may have contributed to different
categories at different time periods.
To account for a possible left-censorship bias, a bias that arises when people who are more
ill are lost to follow-up, as people who may be exposed to certain medications may die
before entering a registry (17), we conducted a subgroup analysis that included only patients
with a new diagnosis of PsA and RA, defined as disease duration of less than one year.
Finally, to account for the demographic differences observed between PsA and RA groups,
we 1:1 matched PsA and RA patients by sex, age and race. In this sub-analysis, age was
matched as younger than 25 being the first category, with 5 year increments after that. Forty
five PsA patients without one of the three matching criteria were not matched. The final
matching RA sample included 2925 patients with 32 malignancies.
Results
There were 4216 PsA and 26133 RA patients enrolled in the registries between August 2003
and October 2010. We excluded 1019 PsA and 5089 RA patients with fewer than 2 visits
during the study period between August 2003 and October 2010 (see Figure 1). We also
excluded 171 PsA and 1486 RA with prior malignancy history documented in the physician
form or patient self-report. We adjudicated 97 malignancies in PsA (40 confirmed, 47 with
recurrent or prior malignancy, 7 “possible”, and 3 non-malignancies) and 648 malignancies
in RA (307 confirmed, 133 “possible”, 165 recurrent or prior, 43 non-malignancies). In both
RA and PsA CORRONA populations, compared to the excluded patients, patients included
in the study were younger, more likely to be Caucasian, had longer disease duration, and
were more likely to use methotrexate and anti-TNF agents (Table 1), although the
magnitude of these differences was relatively small.
Baseline characteristics of PsA and RA groups
The final analysis included 2,970 PsA patients with 7133 PY of follow-up, and 19,260 RA
patients with 53864 PY of follow up. The average follow-up time was 2.79 (SD 2.09) years
for PsA and 2.57 (SD 1.87) years for RA patients. The clinical characteristics of the PsA and
RA groups are shown in Table 2. As expected, PsA patients were younger, included a higher
proportion of men, and a higher proportion of Caucasians, compared to RA patients. PsA
patients also had a higher BMI, a shorter disease duration, were more likely to consume
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alcohol, but were less likely to smoke. The majority of patients in both groups had low-
moderate CDAI scores. Current and “ever” anti-TNF use was higher in the PsA group
compared with RA group, while current or “ever” methotrexate use was higher in the RA
group.
Bivariate malignancy/non-malignancy comparisons within each disease category
Table 2 shows demographic and disease-specific variables for registry patients with and
without malignancy. In both PsA and RA groups, patients with malignancy were older at the
time of the last visit/malignancy diagnosis, had a slightly longer disease duration, and were
more likely to be ex-smokers, but not current smokers. Ninety percent of PsA patients with
malignancy were ever exposed to methotrexate compared to 77% of patients without
malignancy (p=0.045). In the RA group, 91% of patients with malignancy were exposed to
methotrexate compared with 87% of RA patients without malignancy (p=0.054). Forty three
percent of PsA patients with malignancy were currently on anti-TNF, compared with 58% of
PsA patients without malignancy (p=0.051). In the RA group, 29% of patients with
malignancy were currently on anti-TNF compared with 38% of patients without malignancy
(p<0.001).
Malignancy Incidence in PsA and RA
Table 3 describes the type of cancers identified in the registry, and shows the unadjusted
comparison of the malignancy incidence between PsA and RA groups. The overall incidence
of malignancy was similar between the two groups (0.56 (95% CI 0.40, 0.76) per 100 PY for
PsA vs. 0.56 (95% CI 0.50, 0.63) for RA, incidence rate ratio (IRR) =1.00 (95% CI 0.70,
1.36), p=0.86). NMSC was the most common type of cancer identified in both groups (0.21
(95%CI 0.12, 0.35) per 100 PY’s in PsA and 0.20 (95%CI 0.17, 0.24) per 100 PY’s in RA,
IRR 1.05 (95%CI 0.61, 1.80), p=0.85). Lymphoma rates were also similar in PsA vs. RA,
0.04 (0.01, 0.12) vs.0.04 (0.02, 0.06) per 100 PY, IRR1.00 (0.17, 3.11), p=0.67. In addition
to the cancers listed in the table, there were several cancer types in the RA group with only a
small number of reported cases: uterine (4), head and neck (1), bile duct (1), with only one
reported case in the PsA cohort for each of these malignancies.
Multivariate models comparing malignancy incidence in PsA and RA
Poisson regression models for malignancy incidence between PsA and RA are presented in
Table 4. Model 1 includes the entire study population of PsA and RA patients, and defines
drug exposure as “ever exposed.” In this model, older age at the time of the last visit, past
smoking history (but not current smoking history), and cumulative average CDAI are
associated with an increased risk of malignancy, adjusted for sex, disease duration, BMI,
alcohol use, family history of malignancy, and year of enrollment into the registry. Of
particular note, history of methotrexate use (IRR 1.55, 95% CI 1.08, 2.23, p=0.018), but not
history of anti-TNF use, was associated with an increased risk of malignancy in the primary
model. We noted an association between year of enrollment and malignancy incidence that
was incorporated into the multivariable models. Disease duration was also not associated
with an increased risk of malignancy after adjusting for the enrollment period.
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Model 2 includes time-varying drug exposure categories, that includes 2737 PsA patients
with 27 malignancies, and 18160 RA patients with 203 malignancies. In this model, patient
age was associated with an increased risk of malignancy, adjusting for the same factors
adjusted in Model 1. With respect to drug exposure, current methotrexate use (without
current or prior biologic use) was associated with an elevated risk estimate of cancer (IRR
1.77, 95% CI 0.92 – 3.40, p=0.087), although the confidence interval crosses unity).
Importantly, there was no significant difference in the estimated risk of malignancy in PsA
patients compared to RA patients in both models (IRR 1.17 (95% CI 0.82, 1.69), p=0.370 in
Model 1, and 1.18 (95% CI 0.75, 1.85), p=0.473 in Model 2). We also compared malignancy
incidence in PsA and RA using Cox proportional hazard models with age as the underlying
time scale, and obtained similar results after adjusting for the variables used in Model 1 and
Model 2 above (data not shown).
To account for a possible left-censorship bias, we performed a sensitivity analysis that
includes only patients with a new diagnosis of PsA or RA (318 PsA patients with 3
malignancies, and 1786 RA patients with 18 malignancies). Although the numbers of
patients and cancers in this model are small, the risk estimate of malignancy for PsA versus
RA patients was similar (data not shown).
Similarly, in another sensitivity analysis with the age-, sex- and race-matched subgroup of
PsA and RA patients, there was no difference between malignancy rates in PsA compared
with RA (data not shown).
Discussion
Currently, there is a paucity of studies evaluating malignancy risk in PsA patients. Based on
our results, the incidence rate of overall malignancy and cancer subtypes, including NMSC
and lymphoma, were similar in PsA and RA patients in the CORRONA registry, even after
adjusting for multiple potential confounders including age, race, sex, disease activity,
disease duration, year of enrollment, and medication use. Our study has several strengths,
including the large size, diversity and prospective nature of the CORRONA registry.
Information on adverse events was obtained through both patient reports and the treating
rheumatologist. In addition, all reported cases went through a structured confirmation
process using multiple reviewers. This is one of the major strengths of our study design, as
patient or physician reporting alone may not accurate enough for large epidemiologic studies
of cancer incidence (16).
Although our study was not specifically designed to look for an association between
medication exposures and malignancies, we did not find an association between anti-TNF
exposure and cancer in this cohort of patients with inflammatory arthritides. Whether the use
of immunomodulatory medications, specifically the TNF inhibitors, affects cancer risk is
controversial, as TNF has effects not only on inflammation, but also apoptosis, cell survival,
and cancer surveillance.
A 2006 systematic review of randomized control trials found an increased risk of
malignancy in patients with RA treated with anti-TNF therapy (20). In contrast, later
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published metanalyses (21, 22) and both a large Swedish national population based cohort
study (23) and Danish national arthritis registry study (DANBIO)(14, 24) have not been able
to replicate this increased cancer risk in anti-TNF treated RA patients. In addition, a 2011
meta-analysis of prospective, observational studies that included not only patients with RA,
but also patients with PsA and ankylosing spondylitis, did not find an increased risk of solid
malignancy or lymphoma, although it did find an increased risk of skin cancers including
melanoma (25).
Though there is less available data looking specifically at psoriatic disease, a recent meta-
analysis of randomized controlled trials of 6810 patients (5427 with PsO and 1383 patients
PsA) did not observe an increased malignancy risk with the use of anti-TNF inhibitors (26).
In another study, medication exposure also had no effect on malignancy risk in the Canadian
PsA cohort, although only a small percentage of patients (9.7% in the non-malignancy group
and 2.9% of patients in the malignancy group) had been exposed to biologic agents (12).
In contrast to the results for TNF inhibitors, we did find that history of methotrexate
exposure was associated with an increased risk of malignancy in our primary analyses of
this mixed RA/PsA inflammatory arthritis cohort. Since the introduction of methotrexate for
the treatment of inflammatory arthritis and psoriasis, there have been questions regarding its
oncogenicity. Epstein Barr Virus (EBV)-associated lymphoproliferative disorders have been
reported during treatment with low dose MTX treatment in both rheumatoid arthritis (27,
28) and psoriasis (29, 30), although not all lymphoproliferative disorders are associated with
EBV. Regression of these tumors after withdrawal of the drug in some patients is well
described (31).
Possible mechanisms for its association with increased malignancy risk include its
antimetabolic properties and possible decreased cancer surveillance from resulting chronic
immunosuppression (28, 32). These effects are likely to be different when the drug is used
over a relatively finite period in the treatment of malignancies versus the chronic
antimetabolic regimens used to treat RA and PsA.
Conflicting results have been observed from other large cohort studies of RA patients. Three
cohort studies have not found a relationship between methotrexate use and malignancy (33–
35). In contrast, a large cohort of RA patients from the UK receiving non-biologic
DMARDS, of which the large majority (95%) were taking methotrexate alone or in
combination with other DMARDs, found a higher incidence of malignancy as compared to
the general population (24). A recent pharmacoepidemiologic study from the RA cohort in
the CORRONA registry also reported a higher risk of cancer for patients on methotrexate
compared to other non-biologic DMARDs (36).
In psoriasis patients, two small cohort studies did not find an increase risk of malignancy
with methotrexate exposure (37, 38), while one larger U.S. cohort study of 1,380 PUVA
treated patients found an increased risk of lymphoma in those with over 3 years of
methotrexate exposure as compared to the general population (39). Thus, there is conflicting
evidence on the risk of malignancy associated with methotrexate use. These conflicting
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results are likely due to a variety of factors, including differences in study design,
comparator drugs, background population, exposure definitions and duration of follow-up.
We recognize that studies reporting the association between any DMARD use and
malignancy in data registries and retrospective studies could be influenced by a number of
factors, including unmeasured residual confounders, underreporting, and selection bias.
Therefore, neither our study results, nor the results of other observational studies, are
conclusive on this issue. Nevertheless, even with these acknowledged uncertainties, we
believe that our findings suggest that further research is needed on malignancy risk
associated with methotrexate. Of equal importance, our study adds to the growing literature
from registries that TNF inhibitors are not associated with increased malignancy risk.
Since skin cancer is of special concern in PsO and PsA (40), we also compared NMSC rates
between CORRONA and several historical control populations to place our findings in a
context of previously reported NMSC rates. The highest incidence comes from north-central
New Mexico cohort, a high risk geographic area due to a high UV light index, where the
overall incidence rates of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)
were 0.93 and 0.36 per 100 PY’s respectively for men, and 0.49 and 0.15 for BCC and SCC
respectively for women (41). A lower incidence was found in a Minnesota cohort with rates
of BCC were 0.03 and 0.02 per 100 PY’s in women and men, respectively. SCC incidence
rate was 0.004 per 100 PY’s in both genders (42). Lower rates in this cohort may be
explained by a lower median age (33.3 years) in this study and relative low UV light index
in this area. The overall rate of NMSC in the CORRONA PsA cohort of 0.21 per 100 PY’s
falls in the middle of these two high and low risk populations. The incidence rate is also
similar to national incidence estimated by Miller and Weinstock, with a SCC incidence of
0.03 and 0.08 per 100 PY in women and men respectively, and BCC incidence of 0.21 and
0.41 per 100 PY’s in women and men (43).
Importantly, the incidence of NMSC of the CORRONA PsA group may vary from what has
been reported in the psoriasis literature, where higher rates of NMSC have been reported.
Since skin directed therapy, including both psoralen-ultraviolet A (PUVA) and ultraviolet B
(broad band and narrow-band), is indicated for cutaneous but not rheumatologic disease
activity, cutaneous-predominant psoriasis patients may be more likely to experience the pro-
carcinogenic effects of light therapy than patients with more active joint disease. This
concept is supported by a recent review of the clinical trial safety analysis of etanercept in
RA, PsA, and PsO, wherein the rate of squamous cell carcinoma in psoriasis etanercept-
treated patients, but in neither RA nor PsA, was significantly elevated (44). Whether this is
due to variable rates of light therapy exposure in the PsA and PsO groups or related to other
pathogenic exposures or biological processes remains unknown.
There are several limitations to this study. The information about skin disease in PsA
patients and axial involvement was not available in the CORRONA registry during the study
period, and, therefore, we were unable to adjust for these variables in our analyses. More
detailed information on severity of skin disease and spinal involvement were added to the
PsA data collection forms beginning in early 2013, but were not available for the study
period. Furthermore, the overall number of malignancy events was modest for the PsA
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cohort, which may affect the precision of risk estimates for PsA. Nevertheless, it should be
noted that the PsA cohort in the CORRONA registry is one of the largest PsA registries to
our knowledge.
Although formal comparisons cannot be made due to the methodological differences
between the CORRONA registry and data from other studies, the overall rates of
malignancy ascertained in our study were similar to the rates reported in the recent meta-
analysis of randomized trials of RA patients treated with biologic therapy (45). On the other
hand, the malignancy rates in the CORRONA registry were noted to be approximately 50%
lower than the rates reported in the RA population from the DANBIO registry (a Danish
database of arthritis patients)(14). Like many registry studies, we recognize that there may
be malignancy cases that were not reported during study visits by patients or treating
providers, leading to underascertainment. However, systematic underascertainment in both
PsA and RA CORRONA registries should not limit the internal validity of our study results
on the comparative cancer risk in RA versus PsA participants. A small number of
malignancy cases were not confirmed due to lack of supporting source documents, despite
multiple attempts by the registry to obtain such information. It is also possible that a higher
proportion of these patients did develop incident malignancies but were lost to follow-up,
since cancer treatment or mortality may affect ability to comply arthritis care and study
visits. Because of patient confidentiality considerations, there is no patient identifying data
in the CORRONA registry that would allow us to link our data to the National Death Index
database to check for unreported cancer cases. In addition, it is possible that the rates of
malignancy could be different in the US where the penetration of biologic drugs is higher
than that found in European registries, although this would not affect RA versus PsA
patients differentially and should not impact the internal validity of our study results.
Since the main objective of this analysis was to compare incident malignancies in PsA and
RA, we excluded individuals with only one registry visit. Therefore, some of the
malignancies may have not been captured because of loss to follow up, leading to a possible
selection bias. However, this selection bias would not be differentially affected by the
disease status (PsA vs. RA), and should not affect the conclusions of our study. Despite of
these limitations, this is the first study to investigate malignancy incidence in a large U.S.
cohort of patients with PsA, and to compare the incidence of malignancy between patients
with PsA and RA. Therefore, these data are particularly relevant when evaluating the
comparative incidence of malignancy in a US population.
As the available treatments for inflammatory arthritis expand, more emphasis is being
placed on treating associated comorbidities and determining adverse events from therapy. In
comparing the two cohorts with inflammatory arthritis, we did not observe an increased
cancer risk in patients with PsA as compared to RA across malignancy subtypes.
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Figure 1.
Inclusion/Exclusion criteria flow chart
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Table 4
Poisson regression models estimating malignancy risk (Incidence rate ratio) in PsA compared with RA*
Model 1 Model 2
PsA vs. RA 1.17 (p=0.370)(0.82, 1.69) 1.18 (p=0.473)(0.75, 1.85)
Age, 5 year increments 1.21 (p=0.000)(1.16, 1.27) 1.24 (p=0.000)(1.17, 1.31)
Male 1.17 (p=0.200)(0.92, 1.49) 1.23 (p=0.167)(0.92, 1.64)
Disease Duration, 1 year increments 1.03 (p=0.212)(0.98, 1.08) 1.03 (p=0.280)(0.97, 1.10)
BMI 1.00 (p=0.942)(0.98, 1.02) 1.00 (p=0.963)(0.98, 1.02)
Smoking status
  Never smoked 1.00
  Current smoker 1.08 (p=0.677)(0.75, 1.55) 0.85 (p=0.483)(0.53, 1.35)
  Past smoker 1.43 (p=0.003)(1.13, 1.81) 1.19 (p=0.238)(0.89, 1.58)
Alcohol use 1.02 (p=0.893)(0.81, 1.26) 1.04 (p=0.784)(0.79, 1.37)
Family history of cancer 0.98 (p=0.848)(0.79, 1.21) 1.12 (p=0.384)(0.86, 1.46)
CDAI, cumulative average 0.93 (p=0.041)(0.88, 1.00) 0.94 (p=0.130)(0.86, 1.02)
Year of enrollment
  before 2004 1.00 1.00
  2005–2006 0.57 (p=0.002)(0.41, 0.81) 0.63 (p=0.037)(0.40, 0.97)
  2007–2008 1.56 (p=0.000)(1.22, 1.99) 1.91 (p=0.000)(1.42, 2.56)
  2009–2010 1.16 (p=0.532)(0.72, 1.88) 1.54 (p=0.124)(0.89, 2.67)
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Table 5
Poisson regression models estimating malignancy risk (Incidence rate ratio) in PsA compared with RA*
(Continued)
Model 1 Model 2
History of medication exposure
  non-methotrexate DMARD 1.00
  methotrexate 1.55 (p=0.018)(1.08, 2.23)
  anti-TNF 1.05 (p=0.692)(0.84, 1.31)
  other Biologic 1.14 (p=0.513)(0.77, 1.69)
Current medication use
  non-methotrexate DMARD without current or history of methotrexate or biologic 1.00
  methotrexate, no current or prior biologic use 1.77 (p=0.087)(0.92, 3.40)
biologic, no current or prior methotrexate use 1.42 (p=0.427)(0.60, 3.34)
  biologic with current or prior methotrexate use 1.29 (p=0.449)(0.67, 2.48)
  non-methotrexate DMARD, prior methotrexate, but no current or history of
biologic
1.60 (p=0.319)(0.64, 4.02)
*
Results shown as Incident rate ratios with 95% confidence intervals and p-values
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